SEC filings · customer concentration · RIGL

Rigel Pharmaceuticals's major customers

Mckesson Specialty Care Distribution accounted for 42% of Rigel Pharmaceuticals's revenue in FY 2025, about the same as 45% a year earlier.

3major customers now
75%of revenue from them
0listed suppliers depending on it
2011–2026years covered
Free

Get an email when Rigel Pharmaceuticals's customer concentration changes

When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.

Major customers of Rigel Pharmaceuticals

Customers that Rigel Pharmaceuticals named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.

CustomerShare of revenueChange vs prior yearHistoryLatest filing
Mckesson Specialty Care Distribution42%from 45%FY 2018: 11%FY 2019: 30%FY 2020: 23%FY 2021: 20%FY 2022: 31%FY 2023: 43%FY 2024: 45%FY 2025: 42%8 yearsFY 2025 · filed 3 Mar 2026
CencoraCOR19%from 20%FY 2022: 17%FY 2023: 21%FY 2024: 20%FY 2025: 19%4 yearsFY 2025 · filed 3 Mar 2026
Lilly14%newFY 2025: 14%1 yearFY 2025 · filed 3 Mar 2026

Formerly disclosed

CustomerShare of revenueChange vs prior yearHistoryLatest filing
AstraZenecaAZN100%last FY 2014FY 2012: 44%FY 2013: 80%FY 2014: 100%3 yearsFY 2014 · filed 8 Mar 2016
Merck & Co.MRK89%last FY 2011FY 2011: 89%1 yearFY 2011 · filed 4 Mar 2014
Bristol Myers SquibbBMY82%last FY 2016FY 2015: 60%FY 2016: 82%2 yearsFY 2016 · filed 28 Feb 2019
Ber Gen Bio AS74%last FY 2017FY 2011: 11%FY 2012: 22%FY 2016: 18%FY 2017: 74%4 yearsFY 2017 · filed 27 Feb 2020
Ely Lilly And48%last FY 2021FY 2021: 48%1 yearFY 2021 · filed 5 Mar 2024
Grifols41%last FY 2020FY 2019: 8%FY 2020: 41%2 yearsFY 2020 · filed 7 Mar 2023
Third Party26%last FY 2017FY 2015: 12%FY 2017: 26%2 yearsFY 2017 · filed 28 Feb 2019
Cardinal Healthcare25%last FY 2023FY 2022: 19%FY 2023: 25%2 yearsFY 2023 · filed 5 Mar 2024
Asd Healthcare And Oncology Supply21%last FY 2023FY 2018: 17%FY 2019: 37%FY 2020: 30%FY 2021: 17%FY 2022: 17%FY 2023: 21%6 yearsFY 2023 · filed 5 Mar 2024
Cardinal HealthCAH13%last FY 2024FY 2022: 19%FY 2023: 25%FY 2024: 13%3 yearsFY 2024 · filed 3 Mar 2026
Novartis International12%last FY 2015FY 2015: 12%1 yearFY 2015 · filed 8 Mar 2016
Kissei Pharmaceutical Co.Ltd11%last FY 2024FY 2018: 69%FY 2019: 3%FY 2022: 24%FY 2024: 11%4 yearsFY 2024 · filed 3 Mar 2026
Aclaris TherapeuticsACRS9%last FY 2019FY 2015: 28%FY 2019: 9%2 yearsFY 2019 · filed 2 Mar 2021
Celgene6%last FY 2019FY 2017: 26%FY 2019: 6%2 yearsFY 2019 · filed 2 Mar 2021
Daiichi Sankyo2%last FY 2020FY 2012: 33%FY 2013: 20%FY 2020: 2%3 yearsFY 2020 · filed 2 Mar 2021

About this data

US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.

All companies · Latest dependency shifts · Bulk data and API